Galectin Therapeutics Inc.
GALT
$3.98
-$0.18-4.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.71% | -11.42% | -1.05% | 2.58% | -9.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.04% | -18.15% | 29.99% | -1.09% | 25.41% |
| Operating Income | 59.04% | 18.15% | -29.99% | 1.09% | -25.41% |
| Income Before Tax | 39.20% | 16.17% | -19.71% | -7.59% | -35.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.20% | 16.17% | -19.71% | -7.59% | -35.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.20% | 16.17% | -19.71% | -7.59% | -35.74% |
| EBIT | 59.04% | 18.15% | -29.99% | 1.09% | -25.41% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 40.19% | 18.06% | -17.90% | 23.30% | -29.74% |
| Normalized Basic EPS | 40.34% | 17.86% | -18.02% | -3.11% | -29.92% |
| EPS Diluted | 40.19% | 18.06% | -17.90% | 23.30% | -29.74% |
| Normalized Diluted EPS | 40.34% | 17.86% | -18.02% | -3.11% | -29.92% |
| Average Basic Shares Outstanding | 1.95% | 1.98% | 1.42% | 4.31% | 4.45% |
| Average Diluted Shares Outstanding | 1.95% | 1.98% | 1.42% | 4.31% | 4.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |